Alzamend Other Current Liab from 2010 to 2025

ALZN Stock  USD 1.24  0.03  2.36%   
Alzamend Neuro Other Current Liabilities yearly trend continues to be very stable with very little volatility. Other Current Liabilities is likely to grow to about 3.9 M this year. During the period from 2010 to 2025, Alzamend Neuro Other Current Liabilities quarterly data regression pattern had sample variance of 2.3 T and median of  79,333. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
3.7 M
Current Value
3.9 M
Quarterly Volatility
1.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alzamend Neuro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alzamend Neuro's main balance sheet or income statement drivers, such as Interest Expense of 11 K, Interest Income of 0.0 or Depreciation And Amortization of 43.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Alzamend financial statements analysis is a perfect complement when working with Alzamend Neuro Valuation or Volatility modules.
  
Check out the analysis of Alzamend Neuro Correlation against competitors.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

Latest Alzamend Neuro's Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Alzamend Neuro over the last few years. It is Alzamend Neuro's Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alzamend Neuro's overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Alzamend Other Current Liab Regression Statistics

Arithmetic Mean908,759
Geometric Mean156,687
Coefficient Of Variation166.71
Mean Deviation1,258,202
Median79,333
Standard Deviation1,514,978
Sample Variance2.3T
Range3.9M
R-Value0.76
Mean Square Error1.1T
R-Squared0.57
Significance0.0007
Slope240,405
Total Sum of Squares34.4T

Alzamend Other Current Liab History

20253.9 M
20243.7 M
20233.2 M
20222.9 M
2021 2082.0
202060.7 K
201962.7 K

About Alzamend Neuro Financial Statements

Alzamend Neuro investors utilize fundamental indicators, such as Other Current Liab, to predict how Alzamend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Other Current Liabilities3.7 M3.9 M
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:
Check out the analysis of Alzamend Neuro Correlation against competitors.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(138.31)
Return On Assets
(2.14)
Return On Equity
(44.08)
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.